Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Amycretin s.c. phase 1b/2a

Amycretin s.c. phase 1b/2a

Amycretin · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Amycretin
Population
obesity
Phase
1b/2a
Participants
125
Duration
36 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
amycretin 60 mgobesity36125−24.3 % vs −1.1 %
Δ −23.2 pp
—−0.6 vs −0.1——82.0 vs 60.047.0 vs 60.00.0 vs 0.0—verified
amycretin 20 mgobesity36125−22.0 % vs +2.0 %
Δ −24.0 pp
—−0.3 vs −0.1——79.0 vs 40.053.0 vs 20.03.0 vs 0.0—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (9)
  • amycretin 60 mg · nausea · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
    Nausea 14 (82%), 17 3 (60%), 3 27 (79%), 36 2 (40%), 2 12 (75%), 12 1 (25%), 1 8 (50%), 8 2 (50%), 2
  • amycretin 60 mg · vomiting · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
    Vomiting 8 (47%), 15 3 (60%), 3 18 (53%), 20 1 (20%), 1 4 (25%), 5 0 5 (31%), 5 1 (25%), 1
  • amycretin 60 mg · sae · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
    Yes 0 0 1 (3%), 1 0 0 0 0 0
  • amycretin 60 mg · hba1c · Table 3, Glycated haemoglobin rows
    Estimated change from baseline to EOT –0·6% (0·1) –0·1% (0·2)
  • amycretin 20 mg · weight_eff · Table 3
    Estimated change from baseline to EOT –24·3% (1·9) –1·1% (3·0) –22·0% (1·0) 1·9% (2·5) –16·2% (1·1) 2·3% (1·8) –9·7% (1·3) 2·0% (2·4)
  • amycretin 20 mg · nausea · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
    Nausea 14 (82%), 17 3 (60%), 3 27 (79%), 36 2 (40%), 2 12 (75%), 12 1 (25%), 1 8 (50%), 8 2 (50%), 2
  • amycretin 20 mg · vomiting · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
    Vomiting 8 (47%), 15 3 (60%), 3 18 (53%), 20 1 (20%), 1 4 (25%), 5 0 5 (31%), 5 1 (25%), 1
  • amycretin 20 mg · sae · Table 2
    Yes 0 0 1 (3%), 1 0 0 0 0 0
  • amycretin 20 mg · hba1c · Table 3
    Estimated change from baseline to EOT –0·6% (0·1) –0·1% (0·2) –0·3% (0·1) –0·1% (0·1) –0·2% (0·1) 0·1% (0·1) –0·2% (0·1) –0·1% (0·1)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Amycretin s.c. phase 1b/2a. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/amycretin-s-c-phase-1b-2a/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.